X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2159) 2159
Publication (352) 352
Book Review (247) 247
Conference Proceeding (4) 4
Book Chapter (3) 3
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2032) 2032
humans (1908) 1908
fms-like tyrosine kinase 3 - genetics (1442) 1442
hematology (1035) 1035
leukemia, myeloid, acute - genetics (974) 974
mutation (931) 931
female (908) 908
male (837) 837
oncology (748) 748
adult (687) 687
middle aged (674) 674
animals (637) 637
acute myeloid-leukemia (613) 613
internal tandem duplication (594) 594
prognosis (542) 542
aged (534) 534
mice (509) 509
fms-like tyrosine kinase 3 - metabolism (489) 489
leukemia, myeloid, acute - drug therapy (422) 422
acute myelogenous leukemia (413) 413
acute myeloid leukemia (407) 407
flt3 (403) 403
adolescent (389) 389
fms-like tyrosine kinase 3 (387) 387
aml (382) 382
leukemia (372) 372
abridged index medicus (359) 359
leukemia, myeloid, acute - pathology (344) 344
proto-oncogene proteins - genetics (326) 326
hemic and lymphatic diseases (325) 325
nuclear proteins - genetics (324) 324
mutations (321) 321
cancer (316) 316
fms-like tyrosine kinase 3 - antagonists & inhibitors (314) 314
receptor protein-tyrosine kinases - genetics (286) 286
young adult (271) 271
aged, 80 and over (269) 269
leukemia, myeloid, acute - mortality (260) 260
leukemia, myeloid, acute - metabolism (257) 257
tandem repeat sequences (251) 251
cell line, tumor (239) 239
expression (234) 234
gene (225) 225
acute disease (216) 216
tyrosine (210) 210
research (203) 203
treatment outcome (202) 202
child (201) 201
embryonic structures (200) 200
article (199) 199
genetic aspects (195) 195
leukemia, myeloid, acute - diagnosis (191) 191
leukemia, myeloid - genetics (189) 189
signal transduction (189) 189
chemotherapy (188) 188
gene duplication (188) 188
analysis (187) 187
hemic and immune systems (186) 186
antineoplastic agents - therapeutic use (183) 183
prognostic-significance (179) 179
gene expression (174) 174
mutation - genetics (171) 171
protein kinase inhibitors - pharmacology (171) 171
leukemia, myeloid, acute - therapy (170) 170
tyrosine kinase inhibitor (157) 157
hematology, oncology and palliative medicine (155) 155
gene mutations (152) 152
phosphorylation (152) 152
antineoplastic agents - pharmacology (148) 148
cell biology (145) 145
retrospective studies (143) 143
antineoplastic combined chemotherapy protocols - therapeutic use (142) 142
protein kinase inhibitors - therapeutic use (141) 141
cytogenetics (139) 139
health aspects (139) 139
mice, inbred c57bl (139) 139
constitutive activation (137) 137
apoptosis - drug effects (134) 134
gene expression regulation, leukemic (133) 133
recurrence (133) 133
cells (132) 132
kinases (132) 132
minimal residual disease (132) 132
survival rate (132) 132
apoptosis (131) 131
flow cytometry (131) 131
cell proliferation (129) 129
flt3-itd (129) 129
child, preschool (128) 128
survival analysis (128) 128
immunology (127) 127
karyotyping (127) 127
acute promyelocytic leukemia (125) 125
tandem repeat sequences - genetics (125) 125
leukemia, myeloid, acute - enzymology (123) 123
normal cytogenetics (122) 122
dna mutational analysis (121) 121
disease-free survival (119) 119
fluids and secretions (119) 119
transplantation (119) 119
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2056) 2056
Chinese (68) 68
Japanese (23) 23
Russian (5) 5
German (4) 4
French (1) 1
Korean (1) 1
Serbian (1) 1
Slovak (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 5, pp. 454 - 464
Midostaurin, an oral multitargeted kinase inhibitor, is active in patients with a FLT3 mutation. Among patients with acute myeloid leukemia and this mutation,... 
TRIAL | INTERNAL TANDEM DUPLICATION | WILD-TYPE | MEDICINE, GENERAL & INTERNAL | FAVORABLE PROGNOSIS | ACUTE MYELOGENOUS LEUKEMIA | DISTINCT | TYROSINE KINASE INHIBITOR | SORAFENIB | PHASE-I | YOUNGER | Humans | Middle Aged | Kaplan-Meier Estimate | Staurosporine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Staurosporine - analogs & derivatives | Protein Kinase Inhibitors - adverse effects | Cytarabine - administration & dosage | Leukemia, Myeloid, Acute - mortality | Young Adult | fms-Like Tyrosine Kinase 3 - genetics | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Mutation | Daunorubicin - administration & dosage | Leukemia, Myeloid, Acute - genetics | Staurosporine - administration & dosage | Chemotherapy | Care and treatment | Myelocytic leukemia | Nonlymphoid leukemia | Research | Drug therapy | Cancer | Tyrosine | Medical research | Inhibitor drugs | Myeloid leukemia | Leukemia | Clinical trials | Oncology | Transplantation | Kinases | Patients | Cancer therapies | Survival | Cytarabine | Daunorubicin | Medical prognosis | Point mutation | Death | Remission | Acute myeloid leukemia | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Nature, ISSN 0028-0836, 05/2012, Volume 484, Issue 7397, pp. 260 - 263
Journal Article
Blood, ISSN 0006-4971, 01/2013, Volume 121, Issue 3, pp. 485 - 488
Journal Article
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2014, Volume 20, Issue 12, pp. 2042 - 2048
Abstract The fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutation is associated with a high relapse rate for patients with acute myeloid... 
Hematology, Oncology and Palliative Medicine | Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) | Maintenance | Allogeneic stem cell transplantation | Acute myeloid leukemia | Sorafenib | CHRONIC MYELOGENOUS LEUKEMIA | ALLO-SCT | AML | WILD-TYPE | FLT3 | OPEN-LABEL | IMMUNOLOGY | TRANSPLANTATION | MUTATION | INHIBITOR | HEMATOLOGY | ELDERLY-PATIENTS | ALLELIC BURDEN | Graft vs Host Disease - therapy | Niacinamide - analogs & derivatives | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Humans | Middle Aged | Male | fms-Like Tyrosine Kinase 3 - genetics | Graft vs Host Disease - genetics | Leukemia, Myeloid, Acute - enzymology | Allografts | Graft vs Host Disease - mortality | Adult | Female | Maintenance Chemotherapy | Graft vs Host Disease - etiology | Leukemia, Myeloid, Acute - therapy | Survival Rate | Remission Induction | Niacinamide - administration & dosage | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Phenylurea Compounds - administration & dosage | Aged | Mutagenesis, Insertional | Graft vs Host Disease - enzymology | Leukemia, Myeloid, Acute - genetics | Antimitotic agents | Tyrosine | Stem cells | Phenols | Clinical trials | Jeans (Clothing) | Product development | Transplantation | Antineoplastic agents | Hematopoietic stem cells | Index Medicus
Journal Article
Cancer Cell, ISSN 1535-6108, 02/2014, Volume 25, Issue 2, pp. 226 - 242
Cooperative dependencies between mutant oncoproteins and wild-type proteins are critical in cancer pathogenesis and therapy resistance. Although spleen... 
ONCOLOGY | IN-VIVO | THERAPEUTIC TARGET | BCR-ABL | MYELOGENOUS LEUKEMIA | CHRONIC LYMPHOCYTIC-LEUKEMIA | RISK MYELODYSPLASTIC SYNDROME | TYROSINE KINASE 3 | INHIBITOR | MOUSE MODELS | MLL-REARRANGED LEUKEMIA | CELL BIOLOGY | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Phosphorylation | Cell Proliferation | Protein-Tyrosine Kinases - metabolism | Humans | Leukemia, Myeloid, Acute - metabolism | Drug Resistance, Neoplasm | Intracellular Signaling Peptides and Proteins - metabolism | Immunoenzyme Techniques | fms-Like Tyrosine Kinase 3 - genetics | Protein-Tyrosine Kinases - genetics | Antimetabolites, Antineoplastic - pharmacology | Intracellular Signaling Peptides and Proteins - genetics | Real-Time Polymerase Chain Reaction | Syk Kinase | Leukemia, Myeloid, Acute - pathology | Intracellular Signaling Peptides and Proteins - antagonists & inhibitors | RNA, Messenger - genetics | Cells, Cultured | Survival Rate | Mutation - genetics | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | fms-Like Tyrosine Kinase 3 - metabolism | Leukemia, Myeloid, Acute - mortality | Animals | Cell Transformation, Neoplastic | Fluorouracil - pharmacology | Mice | Mice, Inbred BALB C | Protein Kinase Inhibitors - pharmacology | Apoptosis | Protein-Tyrosine Kinases - antagonists & inhibitors | Proteins | Medical colleges | Analysis | Index Medicus | AML | MPD | SYK | FLT3-ITD | MYC | tyrosine kinase | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Cancer, ISSN 0008-543X, 08/2017, Volume 123, Issue 15, pp. 2867 - 2874
Sorafenib has shown encouraging results in patients with Fms‐like tyrosine kinase 3 (FLT3)‐positive acute myeloid leukemia. When used as a maintenance agent... 
acute myeloid leukemia (AML) | allogeneic stem cell transplantation | Fms‐like tyrosine kinase 3 (FLT3) | sorafenib | maintenance | Fms-like tyrosine kinase 3 (FLT3) | AML | INTERNAL TANDEM DUPLICATION | CONTROLLED-TRIAL | FLT3 MUTATIONS | COMBINATION | YOUNGER | THERAPY | ONCOLOGY | OUTCOMES | PHASE-I | REMISSION | Niacinamide - analogs & derivatives | Humans | Middle Aged | Hematopoietic Stem Cell Transplantation | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Transplantation, Homologous | Feasibility Studies | Graft vs Host Disease | Young Adult | fms-Like Tyrosine Kinase 3 - genetics | Disease-Free Survival | Adolescent | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Maintenance Chemotherapy | Retrospective Studies | Chemotherapy, Adjuvant | Leukemia, Myeloid, Acute - genetics | Usage | Transplantation | Stem cells | Graft-versus-host reaction | Toxicity | Leukemia | Medical services | Clinical trials | Stem cell transplantation | Reduction | Quality | Remission | Protein-tyrosine kinase | Tyrosine | Myeloid leukemia | Feasibility studies | Maintenance | Disease control | Patients | Survival | Hemopoiesis | Flt3 protein | Feasibility | Mutation | Acute myeloid leukemia | Cancer | Index Medicus | Abridged Index Medicus | Life Sciences | Hematology | Human health and pathology
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 8, pp. 1061 - 1075
Journal Article
Journal of Biological Chemistry, ISSN 0021-9258, 04/2011, Volume 286, Issue 13, pp. 10918 - 10929
Journal Article